Cargando…

Increased pathologic complete response are expected in HER2-positive and triple-negative locally advanced breast cancers

Detalles Bibliográficos
Autor principal:	Altundag, Kadri
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5424415/ https://www.ncbi.nlm.nih.gov/pubmed/28486984 http://dx.doi.org/10.1186/s40880-017-0208-5

Ejemplares similares

Indolent triple negative breast cancer patients are more likely to develop late relapse compared to triple negative breast cancer patients with a high proliferation index
por: Altundag, Kadri
Publicado: (2023)

Comment on ‘Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy'
por: Altundag, Kadri
Publicado: (2017)

Comment on “Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer”
por: Altundag, Kadri
Publicado: (2017)

Letter comments on: Drug–drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of patients with metastatic breast cancer
por: Altundag, Kadri
Publicado: (2022)

Comment to “Patients with Concordant Triple-Negative Phenotype between Primary Breast Cancers and Corresponding Metastases Have Poor Prognosis”
por: Altundag, Kadri
Publicado: (2016)

Immune evasion might affect survival in laryngeal cancer patients with blood group O
por: Altundag, Kadri
Publicado: (2017)

Comparison of Clinico-Pathological Presentations of Triple-Negative versus Triple-Positive and HER2 Iraqi Breast Cancer Patients
por: Alwan, Nada A. S., et al.
Publicado: (2019)

Complete pathological response in patients with locally advanced cancer of breast and positive Her2/neu with neoadjuvant chemotherapy
por: Cedeño, Heidy, et al.
Publicado: (2007)

Clearance of ctDNA in triple-negative and HER2-positive breast cancer patients during neoadjuvant treatment is correlated with pathologic complete response
por: Ciriaco, Nikaoly, et al.
Publicado: (2022)

Addition of granulocyte-colony stimulating factor (G-CSF) may further increase chemosensitive state in premenopausal node-positive breast cancer patients with induced angiogenesis after surgery
por: Altundag, Kadri, et al.
Publicado: (2004)

Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-Analysis
por: Ma, Xuelei, et al.
Publicado: (2016)

HER2 positivity in patients with estrogen receptor (ER) positive breast cancer: Is it really prognostic?
por: Batra, Atul, et al.
Publicado: (2020)

Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab
por: Li, Jie, et al.
Publicado: (2020)

SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
por: Bartsch, Rupert
Publicado: (2021)

Mammary adipocytes protect triple-negative breast cancer cells from ferroptosis
por: Xie, Yizhao, et al.
Publicado: (2022)

The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients
por: Machleidt, Anna, et al.
Publicado: (2013)

Novel therapy for locally advanced triple-negative breast cancer
por: YAMADA, ATSUKO, et al.
Publicado: (2015)

Roles of MALAT1 in development and migration of triple negative and Her-2 positive breast cancer
por: Xiping, Zhang, et al.
Publicado: (2017)

Molecular Mechanisms Associated with Brain Metastases in HER2-Positive and Triple Negative Breast Cancers
por: Bryan, Sarah, et al.
Publicado: (2021)

Reply to Letter to Editor: “HER2 positivity in patients with estrogen receptor (ER) positive breast cancer: Is it really prognostic?”
por: Li, Shuai, et al.
Publicado: (2020)

Positive- and Negative-Pressure Ventilation Characterized by Local and Global Pulmonary Mechanics
por: Dong, Shoujin, et al.
Publicado: (2022)

Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy
por: Santonja, Angela, et al.
Publicado: (2018)

Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer
por: Nakashoji, Ayako, et al.
Publicado: (2017)

Hydrophobic Proteome Analysis of Triple Negative and Hormone-Receptor-Positive-Her2-Negative Breast Cancer by Mass Spectrometer
por: Lu, Ming, et al.
Publicado: (2010)

Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer
por: Vos, Hanne, et al.
Publicado: (2021)

Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial
por: Demir, Atakan, et al.
Publicado: (2020)

Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer
por: Domergue, Camille, et al.
Publicado: (2022)

Disease-free survival landmark analysis: a potential critical endpoint in triple-negative breast cancer
por: Zheng, Fangchao, et al.
Publicado: (2022)

Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism
por: Schoellhammer, Hans F, et al.
Publicado: (2014)

Genomic Insights into Triple-Negative and HER2-Positive Breast Cancers Using Isogenic Model Systems
por: Mudvari, Prakriti, et al.
Publicado: (2013)

Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis
por: Alanko, Johanna, et al.
Publicado: (2021)

Sociodemographic, Clinical, and Pathological Factors Influencing Outcomes in Locally Advanced Triple Negative Breast Cancer: A Brazilian Cohort
por: da Silva, Jesse Lopes, et al.
Publicado: (2020)

Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer
por: Gass, Paul, et al.
Publicado: (2018)

Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer – single hospital experience
por: Sivina, Elina, et al.
Publicado: (2023)

Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer
por: Chen, Hai-long, et al.
Publicado: (2021)

Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer
por: Aleskandarany, Mohammed A, et al.
Publicado: (2012)

Circulating miRNAs in HER2-Positive and Triple Negative Breast Cancers: Potential Biomarkers and Therapeutic Targets
por: Gupta, Ishita, et al.
Publicado: (2020)

Establishment and characterization of novel highly aggressive HER2-positive and triple-negative breast cancer cell lines
por: Thongchot, Suyanee, et al.
Publicado: (2021)

Multi-Gene Prognostic Signatures and Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in ER-Positive, HER2-Negative Breast Cancer Patients
por: Mazo, Claudia, et al.
Publicado: (2020)

Androgen Receptor as a Predictive Marker for Pathologic Complete Response in Hormone Receptor–Positive and HER-2–Negative Breast Cancer with Neoadjuvant Chemotherapy
por: Lee, Eun-Gyeong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hdpf81nmmid7ls8kfvmo3sqo5g